Topline data from the LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory DMD patients expected 3Q 2023. Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer expected 1H 2024. Topline data from the Pancreatic Cancer Action Network Precision Promise Phase 3 study of pamrevlumab in metastatic pancreatic cancer. Anticipate the filing of up to two INDs: FG-3165 1Q 2024 and FG-3163 4Q 2023. Anticipate the initiation of a Phase 2 trial of FG-3246, a first-in-class antibody-drug conjugate targeting a novel epitope on CD46 for metastatic castration-resistant prostate cancer in 2H 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FGEN:
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- FibroGen put volume heavy and directionally bearish
- FGEN Slides after DMD Candidate Fails In Phase 3 Trial
- FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy